Key points are not available for this paper at this time.
Abstract Eighteen patients with active rheumatoid arthritis were treated with gold sodium thiomalate (Myochrysine®) in this prospective clinical and metabolic study. Myochrysine and 195 Au‐labeled Myochrysine were given at various times while the patients were hospitalized on a metabolic ward. Weekly gold excretion was determined from complete collection of urine and feces while in the hospital. Neutron activation analysis measured stable gold ( 197 Au) content and radiometric analysis assayed 195 Au activity. Weekly excretion of urine and total stable gold (total gold administered to date) and radiogold (current administered dose) did not correlate with clinical course or toxicity. There was a positive relationship between favorable course and fecal hypoexcretion of stable and radioactive gold, an observation requiring additional study and confirmation.
Gottlieb et al. (Wed,) studied this question.